Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Star Diamond: High Modelled Diamond Prices and High Proportions of Type IIa Diamonds (click to learn more) Northstar Discovers Large Near Surface EM Conductor SE of Cam Copper Mine (click to learn more) Xcyte Digital Corp. Releases "Xperience" Subscription Service (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News VIVESTO ADR OASMY

Healthcare Biotechnology Drug Manufacturers - Specialty & Generic
Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics,... see more

Recent & Breaking News (GREY:OASMY)

Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division

GlobeNewswire January 23, 2017

Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)

GlobeNewswire December 21, 2016

Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed

GlobeNewswire December 7, 2016

Interim report for the period May - October 2016

GlobeNewswire December 2, 2016

Communiqué from Extraordinary General Meeting 2016

GlobeNewswire November 22, 2016

Nexttobe Extends Loan to Oasmia Pharmaceutical

GlobeNewswire November 2, 2016

Oasmia Pharmaceutical Announces Change in Ownership

GlobeNewswire November 1, 2016

Change in number of shares and voting rights in Oasmia Pharmaceutical AB (publ)

GlobeNewswire October 31, 2016

Oasmia convenes an extraordinary general meeting on the 21 November, 2016

GlobeNewswire October 26, 2016

Oasmia Pharmaceutical AB Well Positioned for Growth Following Collaborative Agreement, Funding Announcements, and Newly Proposed Executive Leadership

GlobeNewswire October 25, 2016

12 Biggest Mid-Day Gainers For Monday

Benzinga.com  October 24, 2016

Oasmia issues new shares for acquiring an asset corresponding to SEK 25 million

GlobeNewswire October 24, 2016

Oasmia successfully completes private placement of SEK 70 million

GlobeNewswire October 24, 2016

Oasmia Pharmaceutical intends to convene an extraordinary general meeting

GlobeNewswire October 24, 2016

Oasmia enters into collaboration agreement for novel cancer project

GlobeNewswire October 24, 2016

Oasmia announces private placement of new shares

GlobeNewswire October 22, 2016

Oasmia in discussions concerning acquisition of novel cancer project

GlobeNewswire October 21, 2016

Communique from Oasmia's Annual General Meeting 2016

GlobeNewswire September 27, 2016

Sum-Of-The-Parts Valuation Leads Rodman & Renshaw To Initiate Oasmia Pharmaceuticals At Buy With A $6 Target

Benzinga.com  September 12, 2016

Interim report for the period May - July 2016

GlobeNewswire September 2, 2016